TORONTO, Feb. 3, 2021 /CNW/ – Think Research Corporation (TSXV: THNK) or (“Think” or the “Company“) today announced that it has granted 215,000 stock options (each, an “Option“) to a key employee of the Company pursuant to the Company’s Omnibus Equity Incentive Plan at an exercise price of $4.37 per Common Share, with an expiry date that is four years from the grant date. The Options vest as follows: 33% of which vest on February 2, 2022, 33% of which vest on February 2, 2023 and 33% of which vest on February 2, 2024.

Think also announced it has granted 20,000 preferred share units (each, a “PSU“) to a key employee of the Company pursuant to the Incentive Plan. Each PSU represents the right to receive one Common Share upon the achievement of certain performance goals over a defined performance period.

About Think Research Corporation

Think Research is an industry leader in delivering knowledge-based digital healthcare solutions. The Company’s focused mission is to organize the world’s health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process, standardize care, and improve patient outcomes. For over a decade, Think Research’s cloud-based, EMR-agnostic digital tools have empowered clinicians around the world and positively impacted millions of patients across the continuum of care – including primary physician care, acute care hospitals and surgical suites as well as community and seniors care. Think Research is proud to serve as a trusted health system partner to a rapidly growing, global client base that spans three continents and more than 2,200 healthcare facilities.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Think Research Corporation

For further information: Genevieve Tomney, VP, Communications, Think Research, Direct: 416.460.5784, genevieve.tomney@thinkresearch.com